Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 124Myelodysplastic Syndromes 119Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 85Hodgkin Disease 80Leukemia, Lymphocytic, Chronic, B-Cell 77Lymphoma 75Multiple Myeloma 74Lymphoma, Non-Hodgkin 74Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 53Lymphoma, Mantle-Cell 49Lymphoma, Large B-Cell, Diffuse 49Leukemia, Myeloid, Accelerated Phase 49Leukemia, Myelomonocytic, Chronic 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Congenital Abnormalities 47Hematologic Neoplasms 45Leukemia, Myeloid, Chronic-Phase 44Lymphoma, B-Cell, Marginal Zone 43Primary Myelofibrosis 41Burkitt Lymphoma 41Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 33Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Tacrolimus × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00106392 2010-11-23

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

Astellas Pharma Inc

Phase 4 Completed
131 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡